Format

Send to

Choose Destination
See comment in PubMed Commons below
Am J Obstet Gynecol. 2004 Feb;190(2):495-501.

Tinzaparin sodium for thrombosis treatment and prevention during pregnancy.

Author information

  • 1Reference Centre for Haemostatic and Thrombotic Disorders, St Thomas' Hospital, Dublin, Ireland. mark.smith@cdhb.govt.nz

Abstract

OBJECTIVE:

This study was undertaken to assess the pharmacodynamic profile, safety, and efficacy of tinzaparin during pregnancy.

STUDY DESIGN:

Fifty-four pregnant women, 12 for treatment of thrombosis and 42 for thromboprophylaxis, received tinzaparin by once daily injection. Four-hour postdose anti-Xa results were analyzed by use of repeated measures statistical methods.

RESULTS:

One woman (3.4%) on the 175 anti-Xa U/kg dose and three women (20%) on the 50 anti-Xa U/kg dose required a dose increase during the initial dose titration phase to achieve target anti-Xa activity. No thrombotic events occurred.

CONCLUSION:

The 175 anti-Xa U/kg dose is appropriate for treatment and for high-risk thromboprophylaxis throughout pregnancy. In pregnant women at moderate risk of thrombosis, a higher tinzaparin dose is required than in the nonpregnant state and 75 anti-Xa U/kg appears to be appropriate. The majority of women do not need a dose increase with advancing gestation.

PMID:
14981396
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center